Available research platform
Existing EFIRM96 instruments, EPLATE and instrument software are available for delivery. Bulk manufacturing lead times are confirmed during quotation.
Review products and included supportFOR INVESTORS
An electrochemical platform.
A defined development path.
For professional investors, venture capital (VC) and private equity (PE) funds, and family offices exploring EFIRM (Electric Field-Induced Release and Measurement), an upstream platform for molecular research built around instrumentation, consumables and software.
PRODUCTS & DEVELOPMENT STAGES
What is available today.
What comes next.
Demonstrable automated prototype
An automated prototype is available for demonstration with investment organizations and CLIA laboratories. It is not commercially available or clinically validated.
Future research goals
Handheld hardware, smartphone modules and longitudinal molecular data require further engineering, assay validation and research. These are development goals.
PLATFORM THINKING. EVIDENCE-LED DEVELOPMENT.
A technology platform.
A disciplined path forward.
Platform potential
Assay-defined electrochemical detection creates opportunities across nucleic acid and protein research.
Product foundation
EFIRM96 instrumentation, EPLATE consumables and software support customer research and target-specific assay kit development.
Global health ambition
Our long-term goal is to make molecular research more accessible through reproducible assays and practical laboratory workflows.
Discuss the technology, development priorities, intellectual property and commercial strategy with our team. For professional investors; this page is not an investment offer.
THE COMMERCIAL OPPORTUNITY
A platform customers
can build on.
The opportunity begins with useful assays and successful customer adoption.
Serve research and assay developers
Research institutions, laboratories and assay developers can use a common instrument, electrode consumables and software workflow to investigate target-specific questions.
Connect deployment to continued use
Successful instrument adoption can create continuing demand for compatible EPLATE consumables and software-supported workflows as customers repeat studies and develop assays.
Expand through new recognition chemistry
Published work on nucleic acids and proteins suggests routes to further assay applications. Each new target needs its own feasibility work and analytical validation.
Two engagement routes are platform purchasing and joint development of useful assays. For joint work, contributions, background technology, new results, rights retained by EZLife, licensing, publication and commercial returns are negotiated for each project. No fixed ownership share or royalty is implied. Progress depends on laboratory adoption and reproducible application workflows.
Review the scientific foundationWHERE THE PLATFORM CAN GO
Build adoption.
Earn the next application.
Our ambition is to make molecular measurement more accessible through a platform that other researchers and developers can use.
- 01
Establish the laboratory fit
Align EFIRM96, EPLATE and software with the customer’s target, specimen and research objectives.
- 02
Make workflows reproducible
Develop clear protocols, reference materials and analysis methods, then test transfer between laboratories.
- 03
Develop with application partners
Connect the platform with specialist assay chemistry, independent validation and application-specific expertise.
- 04
Expand from demonstrated use
Use evidence from each application to guide the next assay and future improvements in operation and data handling.
Future development depends on research results, resources and partner execution. Product-specific milestones and commercial terms are discussed during diligence.
THE NEXT RESEARCH HORIZON
Molecular information.
Across time.
Our research thesis: reliable longitudinal molecular data is a critical missing layer for future AI-enabled health research.
Establish useful measurements
EFIRM96, EPLATE and software provide a laboratory platform for research and assay development. An automated prototype is available for demonstration and discussion with investment organizations and CLIA laboratories. It is a prototype, not a commercially available or clinically validated product.
Explore accessible sampling
Electrical control and current readout offer a route to miniaturization. Our longer-term goals include handheld instruments and smartphone modules, paired with appropriately validated assays.
Connect biology over time
Repeated saliva sampling could support molecular observations across time and physiological states. Carefully designed cohorts and reproducible measurements could create a data layer for future model-based research.
The path requires hardware development, assay validation, longitudinal studies and responsible data analysis. Handheld and smartphone products, continuous monitoring and AI-based clinical interpretation are future research goals.
Discuss development and prototype demonstrationPLATFORM & BUSINESS
Explore the platform.
Discuss the opportunity.
EZLife Bio’s upstream EFIRM platform brings together EFIRM96 instrumentation, EPLATE consumables and software, enabling customer research and target-specific assay kit development.
From research capability to a defined use case
Evaluate how an instrument and assay workflow fits a laboratory’s target, specimen and analytical objectives.
Discuss the development strategy, commercial priorities and resources needed to advance the platform.
Topics for investor discussions
- Technology & evidence
- Assay-specific performance, reproducibility and comparison methods.
- Products & execution
- EFIRM96, EPLATE, software, customer assay development, team expertise and deployment requirements.
- Intellectual property
- Patent and licensing scope, collaboration terms and freedom to operate.
- Development & capital
- Milestones, commercial strategy, resource needs and financial information.
APPLICATIONS ACROSS BIOLOGY
From human biomarkers to food identity.
Explore published EGFR, exosome, antibody, meat-species and soybean research, alongside genetic-variant and protein-assay development.
Explore research applications →INVESTOR DISCUSSIONS
Understand the company’s next steps.
Products and development stage
Discuss EFIRM96 instrumentation, EPLATE consumables, software and the customer assay development the platform supports.
Scientific evidence
Review target-specific performance, reproducibility, comparison methods and research limitations.
Rights and commercialization
Discuss intellectual property, licensing scope, commercial priorities and execution requirements under agreed confidentiality.
Next milestones
Discuss measurable development objectives, success criteria, risks and resource needs.
Share your investment mandate and areas of interest. The team can arrange an appropriate diligence discussion; please keep the initial inquiry non-confidential.
Send an investor inquiryDiscuss the company and its next milestones.
Contact our team to discuss EZLife Bio’s development priorities, commercial strategy and investor diligence materials.